Skip to main content
Premium Trial:

Request an Annual Quote

Celera Using InforSense's Data Platform

NEW YORK (GenomeWeb News) – InforSense today said that it has "developed a long-term relationship" with Celera, under which the molecular diagnostics firm is using InforSense's Translational Research Solution in automating experimental data analysis and molecular annotation.

London-based InforSense said that it has provided Celera with a translation research platform that will support clinical data browsing, automated integration and analysis of enzyme-linked immunoassays, single nucleotide polymorphisms, and other experimental and public data.

"We wanted to empower our scientists to be able to access and analyze a variety of orthologous clinical and experimental data to support biomarker discovery, and InforSense has provided us with the means to do this," said John Sninsky, vice president of research for Celera, in a statement.

Financial and further terms of the collaboration were not disclosed.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.